Stephens Lowers Definitive Healthcare (NASDAQ:DH) Price Target to $2.00

Definitive Healthcare (NASDAQ:DH) had its price objective dropped by stock analysts at Stephens from $3.00 to $2.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Stephens’ target price suggests a potential upside of 56.25% from the stock’s previous close.

DH has been the subject of a number of other research reports. Wall Street Zen cut Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 28th. Morgan Stanley reaffirmed an “underperform” rating and issued a $3.50 target price on shares of Definitive Healthcare in a report on Thursday, December 18th. William Blair upgraded shares of Definitive Healthcare to a “strong-buy” rating in a research report on Thursday, November 6th. Canaccord Genuity Group lowered their price objective on shares of Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.52.

Definitive Healthcare Stock Down 8.6%

DH opened at $1.28 on Friday. Definitive Healthcare has a one year low of $1.14 and a one year high of $4.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 1.60. The stock has a market capitalization of $180.94 million, a P/E ratio of -1.02 and a beta of 1.59. The business’s 50-day simple moving average is $2.18 and its 200-day simple moving average is $2.87.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DH. Raymond James Financial Inc. purchased a new stake in Definitive Healthcare in the 2nd quarter valued at approximately $32,000. State of Alaska Department of Revenue lifted its holdings in shares of Definitive Healthcare by 109.3% in the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after buying an additional 5,970 shares during the period. Savant Capital LLC purchased a new stake in shares of Definitive Healthcare in the second quarter valued at approximately $45,000. Schonfeld Strategic Advisors LLC acquired a new position in Definitive Healthcare during the fourth quarter worth $35,000. Finally, Los Angeles Capital Management LLC acquired a new position in Definitive Healthcare during the second quarter worth $51,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

More Definitive Healthcare News

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q4 revenue came in roughly in-line to slightly above estimates (reported ~$61.5M vs. some analyst estimates around $59–61M), showing top-line stability versus a year ago. Read More.
• Positive Sentiment: Cash and cash equivalents increased year-over-year (reported ~$163.6M), which supports near-term liquidity. Read More.
• Neutral Sentiment: Reported GAAP EPS results were reported as meeting some consensus figures (sources show EPS in-line with a $0.06 consensus), so headline EPS didn’t surprise to the upside. Read More.
• Neutral Sentiment: Brokerage consensus has settled around a “Hold” average recommendation, reflecting mixed views across analysts. Read More.
• Negative Sentiment: The company cut guidance: Q1 FY2026 EPS guidance (~$0.03) and revenue guidance ($54M–$56M) both sit below consensus, and full‑year 2026 guidance ($0.14–$0.17 EPS; $220M–$226M revenue) also trails Street expectations — the primary driver of today’s downside. Read More.
• Negative Sentiment: Analysts lowered price targets and kept cautious ratings (Canaccord cut its target from $4.00 to $3.00 with a Hold; Stephens trimmed its target to $2.00 with Equal Weight), amplifying selling pressure. Read More.
• Negative Sentiment: Underlying profitability metrics showed deterioration in some reports (wider operating loss and larger net loss year-over-year), and multiple institutional holders trimmed positions in the latest quarter, suggesting reduced confidence from larger investors. Read More.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.